scholarly journals Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain

2015 ◽  
Vol 6 (1) ◽  
Author(s):  
Shuko Takeda ◽  
Susanne Wegmann ◽  
Hansang Cho ◽  
Sarah L. DeVos ◽  
Caitlin Commins ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Weight ◽  
High Molecular Weight ◽  
Neuronal Uptake

High-molecular-weight forms of somatostatin are reduced in Alzheimer's disease and Down's syndrome

1986 ◽  
Vol 63 (2) ◽  
pp. 141-146 ◽  
Author(s):  
Adrian R. Pierotti ◽  
Anthony J. Harmar ◽  
James Simpson ◽  
Celia M. Yates
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Weight ◽  
High Molecular Weight ◽  
Down's Syndrome ◽  
Down’S Syndrome

High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin G

1987 ◽  
Vol 145 (1) ◽  
pp. 241-248 ◽  
Author(s):  
William M. Pardridge ◽  
Harry V. Vinters ◽  
Bruce L. Miller ◽  
Wallace W. Tourtellotte ◽  
Jody B. Eisenberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Weight ◽  
Human Serum ◽  
High Molecular Weight ◽  
Immunoglobulin G ◽  
Amyloid Peptide

scholarly journals Detection of Soluble Amyloid-βOligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Susanne Aileen Funke
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Weight ◽  
High Molecular Weight ◽  
Therapy Monitoring ◽  
Current Status ◽  
Clinical Criteria ◽  
Toxic Species ◽  
Diagnosis And Therapy ◽  
Preclinical Ad

The diagnosis of probable Alzheimer's disease (AD) can be established premortem based on clinical criteria like neuropsychological tests. Post mortem, specific neuropathological changes like amyloid plaques define AD. However, the standard criteria based on medical history and mental status examinations do not take into account the long preclinical features of the disease, and a biomarker for improved diagnosis of AD is urgently needed. In a large number of studies, amyloid-β(Aβ) monomer concentrations in CSF of AD patients are consistently and significantly reduced when compared to healthy controls. Therefore, monomeric Aβin CSF was suggested to be a helpful biomarker for the diagnosis of preclinical AD. However, not the monomeric form, but Aβoligomers have been shown to be the toxic species in AD pathology, and their quantification and characterization could facilitate AD diagnosis and therapy monitoring. Here, we review the current status of assay development to reliably and routinely detect Aβoligomers and high-molecular-weight particles in CSF.

scholarly journals Seed‐competent high‐molecular‐weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients

2016 ◽  
Vol 80 (3) ◽  
pp. 355-367 ◽  
Author(s):  
Shuko Takeda ◽  
Caitlin Commins ◽  
Sarah L. DeVos ◽  
Chloe K. Nobuhara ◽  
Susanne Wegmann ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Weight ◽  
Cerebrospinal Fluid ◽  
Mouse Model ◽  
High Molecular Weight
Sign in / Sign up

Export Citation Format

Share Document